Kidney Cancer Coverage from Every Angle
Editor:
Neeraj Agarwal, MD
Advertisement
Advertisement

Videos

Toni K. Choueiri, MD, on Quality-of-Life Outcomes Reported in KEYNOTE-564 by Patients With RCC

Brian I. Rini, MD, on Clinical Implications of Treatment With Pembrolizumab Plus Axitinib for RCC

Toni K. Choueiri, MD, on KEYNOTE-564: Pembrolizumab in the Adjuvant Treatment of Renal Cell Carcinoma

Samra Turajlic, MBBS, PhD: Shedding Light on Metastases of Renal Cell Tumors

Brian I. Rini, MD, on Using Biomarkers to Inform Treatment Decisions in Renal Cell Carcinoma

Toni K. Choueiri, MD, on Selecting Treatment for Advanced Kidney Cancer: Findings From the CLEAR Trial

Toni K. Choueiri, MD, on Clinical Implications of Treating Clear Cell RCC With Belzutifan Plus Cabozantinib

Sumanta K. Pal, MD, on Using Tivozanib to Treat Progression of Kidney Cancer: Practical Information From the TIVO-3 Trial

Sumanta K. Pal, MD, on Clinical Implications of SWOG 1500 Trial of Cabozantinib for Papillary Kidney Cancer

Rana R. McKay, MD, on the Treatment Landscape for Metastatic RCC

Thomas Powles, MD, PhD: A Look Into the Future of Kidney Cancer Treatment

Toni K. Choueiri, MD, on the Impact of COVID-19 on Patients With Kidney Cancer

Ziad Bakouny, MD, on Sarcomatoid and Rhabdoid RCC: Response to Immune Checkpoint Inhibitors

Toni K. Choueiri, MD, on the Need to Focus on Novel Targets in Renal Cell Carcinoma

David A. Braun, MD, PhD, on Immunogenomics and Immunotherapy in Renal Cell Carcinoma

Rana R. McKay, MD, on Nivolumab and Ipilimumab in Advanced Kidney Cancer

Toni K. Choueiri, MD: Overview of Systemic Kidney Cancer Treatment

Neeraj Agarwal, MD, on the Outlook for Kidney Cancer Treatment

Nizar M. Tannir, MD, on Nivolumab Plus Ipilimumab vs Sunitinib: Choosing Therapy and Managing Toxicities

Eric Jonasch, MD, on How NCCN Clinical Practice Guidelines in Oncology® Updates May Affect Treatment Selection in Metastatic Kidney Cancer

Daniel P. Petrylak, MD, on Supporting Patients Considering a Clinical Trial

Thomas Powles, MD, PhD, on Using Nivolumab and Ipilimumab in Renal Cell Carcinoma

Leonard J. Appleman, MD, PhD, on Pazopanib After Metastasectomy in Renal Cell Carcinoma

Jonathan E. Rosenberg, MD, on Clinical Implications of Adding Bevacizumab to Gemcitabine/Cisplatin in Urothelial Carcinoma

Thomas Powles, MD, PhD, on Renal Cell Carcinoma: Combining Checkpoint Inhibitors With Targeted Treatment

Daniel P. Petrylak, MD, on Toxicities in Nivolumab or Ipilimumab for Urothelial Cancer

Eric Jonasch, MD, on Managing Hepatotoxicity in Patients Treated With Pazopanib

Rana R. McKay, MD, on Kidney Cancer: What Complete Remission Means for Patients

Charles von Gunten, MD, PhD, on Opioids for Managing Cancer Pain

Rana R. McKay, MD, on Renal Cell Carcinomas: The Potential Role for Atezolizumab and Bevacizumab

Simron Singh, MD, MPH, on Patient-Centered Care: Measuring Experience

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on Metastatic RCC: Perspectives on the Carmena Trial

Bernard J. Escudier, MD, on RCC: How the IMmotion151 Results Could Improve Treatment

Eric Roeland, MD, on Prophylactic Strategies for Highly Emetogenic Chemotherapy

Betty R. Ferrell, PhD, on the Impact of Immunotherapy on Patients' Well-Being

Jeremy Warner, MD, on Patient Navigation: The Proactive Approach

Neeraj K. Arora, PhD, on Patient-Centered Care in Clinical Practice

Laurence Albiges, MD, PhD, and Toni K. Choueiri, MD, on RCC: Novel Combinations for Advanced Disease

Ulka N. Vaishampayan, MD, on Renal Cancer: The Personalized Approach to Treatment

Chung-Han Lee, MD, PhD, on Maintaining Weight During Treatment

Eric Jonasch, MD, on Kidney Cancer: Management Updates

Crystal S. Denlinger, MD, and Ann H. Partridge, MD, MPH, on Making Sense of Guidelines and Guidance

A Patient’s Story: NCCN Guidelines for Patients® Helped Me Ask The Right Questions

A Patient's Story: How NCCN Guidelines for Patients® Helped Me and My Caregiver

Jonathan E. Rosenberg, MD, on Nivolumab Monotherapy for Urothelial Carcinoma

Laurence Albiges, MD, PhD, on RCC: Update on Checkpoint Inhibitors

Thomas Powles, MD, on Atezolizumab vs Chemotherapy in Urothelial Carcinoma

Sumanta K. Pal, MD, on Renal Cancer Immunotherapy: Latest Developments

Mollie Reed, MSN, RN, ACNP-BC, on Managing Rash Linked to TKIs

Robert A. Figlin, MD, on Managing TKI-Induced Diarrhea

Rohann J.M. Correa, MD, PhD, on RCC: Ablative Radiation vs Nephrectomy

Anurag Singh, MD, on RCC: Findings From an SBRT Pilot Study

Toni K. Choueiri, MD, and Michael D. Staehler, MD, PhD, on RCC: Results From the SWITCH-II and SURTIME Trials

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on Urothelial, RCC, and Other GU Malignancies: Two Key Trials

Eric Jonasch, MD, on RCC and Sunitinib: Phase II Trial Results

Robert J. Motzer, MD, and Toni Choueiri, MD: Results of the PROTECT Trial

Toni Choueiri, MD, on Newer Agents in the Treatment of Renal Cell Carcinoma

Eric Jonasch, MD, on Kidney Cancer: Incorporating New Systemic Therapies

Robert J. Motzer, MD, on NCCN Kidney Cancer Guidelines: Process, Evolution, and Clinical Practice

Toni K. Choueiri, MD, and Bernard J. Escudier, MD, on RCC: Trial Results on Sunitinib

Emily Lemke, DNP, AGPCNP-BC, AOCNP, on Managing TKI-Induced Diarrhea

Petros Grivas, MD, PhD, on Managing TKI-Induced Diarrhea

Michael B. Atkins, MD, and Eric Jonasch, MD, on Metastatic Renal Cell Carcinoma: Results From the IMmotion150 Trial

The JNCCN Spotlight

Naveen S. Vasudev, PhD, MBChB, on Ipilimumab Plus Nivolumab for RCC: Duration of First-Line Treatment

Copyright © 2021 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.